Sun Pharma Leadership Changes & USFDA Inspection Update

  Published 1 year ago

Sun Pharma announces MD change, Dilip Shanghvi to executive chairman, Kirti Ganorkar appointed; USFDA issues Form 483 after inspection.

  • Dilip Shanghvi transitions to executive chairman, focusing on specialty portfolio growth and strategic oversight.
  • Kirti Ganorkar, a 27-year veteran, led India business growth, expanded specialty drugs, and global markets.
  • USFDA inspects Gujarat facility, issues Form 483 with 8 observations post June 2025 inspection.
You might like these

Bajaj Holdings Sells Bajaj Finserv Stake

DSL Credit Rating: Stable Outlook

Tata Acquires ES‑Tec, Expands ADAS Reach

Rs 11 Lakh Cr Credit Boost for SHGs

BEML FY25 Results: Growth & Efficiency

Meta AI Training: Court Rejects German Injunction

Rupee Flat Amid Geopolitical Tensions, Oil Prices Rise

News that matters the most ⚡